PepGen Inc (PEPG) News

Form 8-K - Current report

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

– The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

– Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable...

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- PepGen Inc. (Nasdaq: PEPG), a...

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

– FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025 – – Study designs of CONNECT program...

PepGen to Participate in Upcoming Investor Conferences

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 8-K - Current report